Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tscan Therapeutics Inc
(NQ:
TCRX
)
4.780
+0.030 (+0.63%)
Streaming Delayed Price
Updated: 3:20 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tscan Therapeutics Inc
< Previous
1
2
3
4
5
Next >
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
October 04, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 29, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
August 13, 2024
Via
Benzinga
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
August 12, 2024
TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
The Analyst Landscape: 7 Takes On TScan Therapeutics
June 04, 2024
Via
Benzinga
Key Takeaways From TScan Therapeutics Analyst Ratings
May 13, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On TScan Therapeutics
April 23, 2024
Via
Benzinga
TScan Therapeutics: Q4 Earnings Insights
March 06, 2024
Via
Benzinga
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 30, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
May 29, 2024
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 13, 2024
TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 09, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
April 24, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 22, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Closing of Upsized Public Offering
April 19, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
April 17, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
April 16, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
April 16, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
April 08, 2024
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
March 22, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
March 17, 2024
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator.
Via
InvestorPlace
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 06, 2024
TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
February 26, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.